In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Nafarelin | Natural peptide Oxytocin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 549 | 3,492 (plus 1,148 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 117 (102 in people) | 157 (152 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 10 · 4 active2 more mention it but do not test it | 690 · 65 active238 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Nafarelin | Oxytocin |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 33126467 | 1503286 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Pitocin says: “Antepartum: medically indicated induction of labor, stimulation or reinforcement of labor, adjunctive therapy in incomplete or inevitable abortion” No central EU authorisation (EMA).
| Anxiety and moodMental health and mood | 11 | 34132417 |
|---|
| Adverse eventsWhole body | 3838 | 1261233 |
|---|
| PainReproductive and sexual health | 88 | 1098524 |
|---|
| PharmacokineticsPharmacology | 4117213 | 9168203 |
|---|
| Bone and jointMusculoskeletal | 5151 | 2020 |
|---|
| Sexual functionReproductive and sexual health | 11 | 7647245 |
|---|
| Body weightMetabolic and weight | 11 | 23176 |
|---|
| Hormone levelsEndocrine and hormones | 66 | 1212 |
|---|
| LipidsMetabolic and weight | 1111 | 541 |
|---|
| Electrolyte balanceEndocrine and hormones | 22 | 13229 |
|---|
| Quality of lifeWhole body | 44 | 22 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Nafarelin differs from Gonadorelin at 2 positions.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 10 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Assistance Publique - Hôpitaux de Paris652 participants27 Jun 2024 to est. 27 Sept 2027
In Vitro Fertilization · ICSI Intracytoplasmic Spermatozoid Injection
University of Oxford159 participantsNov 2009 to May 2013
Infertility
Fundacion Dexeus154 participants14 Oct 2026 to est. 15 Jan 2028
Fertility Preservation
2 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010
Uterine Atony · Postpartum Hemorrhage
Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020
Dystocia
University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019
Post Partum Hemorrhage
238 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Nafarelin | Oxytocin |
|---|---|---|
| Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | 72% Oestradiol suppression n not reported1999 | 12.6% Mean percent change oestradiol Dose studied: 24 IUn = 452020 |
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Nafarelin | Oxytocin |
|---|---|---|
| Body weightMetabolic and weightCompared as: difference from placebo, in g | No comparable result 1 randomized-trial result measure it in another way or another unit. | 196 g Difference in total fat Dose studied: 24 IU four times daily8 weeksn = 612024 |
| Liver fat and liver functionLiverCompared as: difference from placebo, in proportion | No comparable result 3 randomized-trial results measure it in another way or another unit. | −0.01 proportion Difference in liver fat fraction Dose studied: 24 IU four times daily8 weeksn = 612024 |
|---|
| Sexual functionReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 26% FSFI score change Placebo: 31% Dose studied: 32 IU8 weeksn = 302015 |
|---|
| LipidsCardiovascularCompared as: difference from placebo, in mg/dl | No comparable result 1 randomized-trial result measure it in another way or another unit. | −19.3 mg/dL LDL cholesterol change Dose studied: 24 IU 4 times per day8 weeksn = 212021 |
|---|
| PainNervous system and cognitionCompared as: difference from placebo, in % | No comparable result 5 randomized-trial results measure it in another way or another unit. | −11% allodynic area change Dose studied: 100 µgn = 52023 |
|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size | No randomized trial result 41 results from other study designs. | −1.12 effect size Effect size Dose studied: 48 IU/day6 weeksn = 1032020 |
|---|
| Anxiety and moodReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | −20% Score reduction · Shown as a change. The study reports a score reduction of this size. Placebo: −4% Dose studied: 20 IU twice daily in week 1, then 40 IU twice daily8 weeksn = 402013 |
|---|
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 61% Patients reporting hot flushes Placebo: 35% Dose studied: 200 micrograms twice daily3 monthsn not reported1995 | No comparable result 66 randomized-trial results measure it in another way or another unit. |
|---|